Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC
Leona L. Pott, Sascha Hagemann, Henning Reis, et al.
Oncotarget (2017) Vol. 8, Iss. 7, pp. 11950-11962
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

The expression profile and prognostic significance of eukaryotic translation elongation factors in different cancers
Md. Khurshidul Hassan, Dinesh Kumar, Monali Naik, et al.
PLoS ONE (2018) Vol. 13, Iss. 1, pp. e0191377-e0191377
Open Access | Times Cited: 88
Monitoring Cell-Type–Specific Gene Expression Using Ribosome Profiling In Vivo During Cardiac Hemodynamic Stress
Shirin Doroudgar, Christoph P. Hofmann, Etienne Boileau, et al.
Circulation Research (2019) Vol. 125, Iss. 4, pp. 431-448
Open Access | Times Cited: 61
Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment
Chunyang Jiang, Lingxiang Meng, Bingjun Yang, et al.
Clinical Genetics (2019) Vol. 97, Iss. 1, pp. 73-88
Closed Access | Times Cited: 57
Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management
Khaled S. Allemailem, Mohammed A. Alsahli, Ahmad Almatroudi, et al.
Cancer Communications (2022) Vol. 42, Iss. 12, pp. 1257-1287
Open Access | Times Cited: 38
Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3
Ying Zhou, Yaoting Li, Shihao Xu, et al.
International Journal of Cancer (2019) Vol. 146, Iss. 5, pp. 1383-1395
Open Access | Times Cited: 46
CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway
Shuhua Zhang, Fan Zhang, Qing Chen, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 46
CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
Fahreddin Palaz, Mehmet Özsöz, Ali Zarrinpar, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 975-995
Open Access | Times Cited: 5
Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma
Shijing Yu, Ruirui Zhao, Bingchen Zhang, et al.
Asian Journal of Pharmaceutical Sciences (2023) Vol. 18, Iss. 4, pp. 100828-100828
Open Access | Times Cited: 11
Identification of key molecular pathways and genes in BRCA1 and BRCA2-mutant ovarian cancer: evidence from bioinformatics analysis
Aeshah A. Awaji, Abdulkadir Yusif Maigoro, Abdullahi Tunde Aborode, et al.
Genome Instability & Disease (2024) Vol. 5, Iss. 4, pp. 164-182
Closed Access | Times Cited: 4
CRISPR/Cas9: at the cutting edge of hepatology
Francis P. Pankowicz, Kelsey E. Jarrett, William R. Lagor, et al.
Gut (2017) Vol. 66, Iss. 7, pp. 1329-1340
Open Access | Times Cited: 39
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy
Zhaoping Pan, Yujuan Chen, Jingyan Liu, et al.
European Journal of Medicinal Chemistry (2017) Vol. 144, pp. 517-528
Closed Access | Times Cited: 37
Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies
Zheng Zhang, Xiaolan Xing, Peng Guan, et al.
European Journal of Medicinal Chemistry (2021) Vol. 217, pp. 113314-113314
Closed Access | Times Cited: 21
Eukaryotic elongation factors 2 promotes tumor cell proliferation and correlates with poor prognosis in ovarian cancer
Nannan Shi, Xiaojing Chen, Rong Liu, et al.
Tissue and Cell (2018) Vol. 53, pp. 53-60
Closed Access | Times Cited: 27
Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets
Urmila Sehrawat
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10835-10835
Open Access | Times Cited: 2
miR-183-5p acts as a potential prognostic biomarker in gastric cancer and regulates cell functions by modulating EEF2
Wang Li, Xu Cui, Anlong Qi, et al.
Pathology - Research and Practice (2019) Vol. 215, Iss. 11, pp. 152636-152636
Closed Access | Times Cited: 17
CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity
Tao Xu, Li Li, Yuchen Liu, et al.
International Journal of Biological Sciences (2020) Vol. 16, Iss. 13, pp. 2283-2295
Open Access | Times Cited: 15
Characterizing genes associated with cancer using the CRISPR/Cas9 system: A systematic review of genes and methodological approaches
Fernando Gonzalez-Salinas, Claudia Martínez-Amador, Víctor Treviño
Gene (2022) Vol. 833, pp. 146595-146595
Closed Access | Times Cited: 9
Circular RNA hsa_circ_0098181 inhibits metastasis in hepatocellular carcinoma by activating the Hippo signaling pathway via interaction with eEF2
Ping Gao, Yuan Yang, Wei Li, et al.
Annals of Hepatology (2023) Vol. 28, Iss. 5, pp. 101124-101124
Open Access | Times Cited: 4
The role of differentially expressed genes and immune cell infiltration in the progression of nonalcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC): a new exploration based on bioinformatics analysis
Yang Liu, Xiaohan Yu, Yuegu Wang, et al.
Nucleosides Nucleotides & Nucleic Acids (2024), pp. 1-16
Closed Access | Times Cited: 1
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Ruiting Li, Qin Wang, Kaiqin She, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 7
Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers
Patricia Chen, Liting You, You Lü
The CRISPR Journal (2018) Vol. 1, Iss. 1, pp. 47-54
Closed Access | Times Cited: 11
What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review
Shumin Li, Yanjing Li, Yuxian Bai
European Journal of Pharmacology (2019) Vol. 857, pp. 172470-172470
Closed Access | Times Cited: 9
The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase
Kwangwoon Lee, Eric A. Kumar, Kevin N. Dalby, et al.
Protein Science (2019) Vol. 28, Iss. 12, pp. 2089-2098
Open Access | Times Cited: 7
CRISPR/Cas9 in Gastrointestinal Malignancies
André Jefremow, Markus F. Neurath, Maximilian J. Waldner
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 7
Calyxin Y sensitizes cisplatin-sensitive and resistant hepatocellular carcinoma cells to cisplatin through apoptotic and autophagic cell death via SCF βTrCP-mediated eEF2K degradation
Chao Zhang, Jian-Li Lei, Hao Zhang, et al.
Oncotarget (2017) Vol. 8, Iss. 41, pp. 70595-70616
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top